WHO Media
| Friday 22 January, 2021 Please find enclosed the link of the WHO Director-General's statement as well as other materials from the COVID-19 media briefing on 22 January and more: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-22-january-2021 - Yesterday, the United States of America announced that it plans to retain its membership in WHO. We welcome President Biden’s commitment not just to remaining part of the WHO family, but to working constructively with WHO, its Member States and the multilateral system to end the pandemic and address the many health challenges we face globally.
- Today I’m glad to announce that COVAX has signed an agreement with Pfizer/BioNTech for up to 40 million doses of its vaccine.
- COVAX is on track to deliver 2 billion doses by the end of year.
- It’s important we all remember that vaccines will complement, but not replace, the proven public health measures that have been shown to suppress transmission and save lives.
Media briefing audio link (Length 1hr 08mins):
https://terrance.who.int/mediacentre/presser/WHO-AUDIO_Emergencies_Coronavirus_Press_Conference_22JAN2021.mp3 News edit link (TRT 4mins 24 sec): https://who.canto.global/b/V456T Media assets and information on COVID-19
https://who.canto.global/v/coronavirus
Related: - COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
- Additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca.
- COVAX is therefore on track to deliver at least 2 billion doses by the end of the year, including at least 1.3 billion doses to 92 lower income economies in the Gavi COVAX AMC.
Read more here.  |
No comments:
Post a Comment